CO5280075A1 - DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY - Google Patents
DROSPIRENONE FOR HORMONE REPLACEMENT THERAPYInfo
- Publication number
- CO5280075A1 CO5280075A1 CO01003045A CO01003045A CO5280075A1 CO 5280075 A1 CO5280075 A1 CO 5280075A1 CO 01003045 A CO01003045 A CO 01003045A CO 01003045 A CO01003045 A CO 01003045A CO 5280075 A1 CO5280075 A1 CO 5280075A1
- Authority
- CO
- Colombia
- Prior art keywords
- estrogen
- active agent
- drospirenone
- carbolactone
- preg
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica que comprendecomo un primer agente activo, un estrógeno (o derivado natural o sintético del mismo) en cantidades suficientes para tratar enfermedades, desórdenes y síntomas asociados con niveles endógenos deficientes de estrógeno en mujeres, y como un segundo agente activo, 6ß, 7ß, 15ß, 16ß-dimetilen-3-oxo-17a-preg-4-eno-27,17-carbolactona (drospirenona) en cantidades suficientes para proteger el endometrio de los efectos adversos del estrógeno, conjuntamente con un excipiente o portador farmacéuticamente aceptable. Una composición farmacéutica que comprende estradiol como un primer agente activo en cantidades que corresponden a una dosis diaria de 1 a 3 mg para tratar enfermedades, desórdenes y síntomas asociados con niveles endógenos deficientes de estrógeno en mujeres, y como un segundo agente activo 6ß, 7ß, 15ß, 16ß-dimetilen-3-oxo-17a-preg-4-eno-27,17-carbolactona (drospirerona) en cantidades suficientes que corresponden a una dosis diaria de 1 a 3,5 mg para proteger el endometrio de los efectos adversos del estrógeno, junto con un excipiente o portador farrnacéuticamente aceptable.Una preparación farmacéutica multi-fásica que consiste en un número de unidades de dosificación diarias separadamente envasadas e individualmente removibles dispuestas dentro de una unidad de envase destinadas a administración oral durante un periodo de al menos 21 días donde dichas unidades de dosificación diarias comprenden una combinación de estradiol en una cantidad en el rango de desde aproximadamente 0,1 a 5 mg y drospirenona en el rango de desde aproximadamente 0,25 a 6 mg.A pharmaceutical composition comprising as a first active agent, an estrogen (or natural or synthetic derivative thereof) in amounts sufficient to treat diseases, disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active agent, 6β, 7ß, 15ß, 16ß-dimethylene-3-oxo-17a-preg-4-eno-27.17-carbolactone (drospirenone) in amounts sufficient to protect the endometrium from the adverse effects of estrogen, together with a pharmaceutically acceptable carrier or excipient . A pharmaceutical composition comprising estradiol as a first active agent in amounts corresponding to a daily dose of 1 to 3 mg to treat diseases, disorders and symptoms associated with endogenous estrogen deficient levels in women, and as a second active agent 6ß, 7ß , 15ß, 16ß-dimethylene-3-oxo-17a-preg-4-eno-27.17-carbolactone (drospirerona) in sufficient amounts corresponding to a daily dose of 1 to 3.5 mg to protect the endometrium from effects adverse effects of the estrogen, together with a pharmaceutically acceptable carrier or excipient. A multi-phase pharmaceutical preparation consisting of a number of separately dosed and individually removable daily dosage units disposed within a container unit intended for oral administration during a period of at least minus 21 days where said daily dosage units comprise a combination of estradiol in an amount in the range of from apr approximately 0.1 to 5 mg and drospirenone in the range of from about 0.25 to 6 mg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00200183 | 2000-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5280075A1 true CO5280075A1 (en) | 2003-05-30 |
Family
ID=38170612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01003045A CO5280075A1 (en) | 2000-01-18 | 2001-01-17 | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR035633A1 (en) |
| CO (1) | CO5280075A1 (en) |
| HR (1) | HRP20070360B1 (en) |
| JO (1) | JO2334B1 (en) |
| PE (1) | PE20011051A1 (en) |
| SA (1) | SA01210754B1 (en) |
| UA (2) | UA89180C2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (en) * | 1994-07-27 | 1996-02-01 | Schering Ag | Use of a combination product containing a competitive progesterone antagonist and a progestogen for the manufacture of a medicament for the treatment of endometriosis or Leiomyomata uteri |
| DE19654609A1 (en) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutic progestogens for the treatment of premenstrual dysphoric disorder |
| KR101019361B1 (en) * | 1999-08-31 | 2011-03-07 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
-
2001
- 2001-01-11 JO JO200110A patent/JO2334B1/en active
- 2001-01-15 PE PE2001000035A patent/PE20011051A1/en active IP Right Grant
- 2001-01-17 CO CO01003045A patent/CO5280075A1/en not_active Application Discontinuation
- 2001-01-17 AR ARP010100199 patent/AR035633A1/en not_active Application Discontinuation
- 2001-01-18 UA UAA200612100A patent/UA89180C2/en unknown
- 2001-01-18 UA UA2002086809A patent/UA81388C2/en unknown
- 2001-03-21 SA SA01210754A patent/SA01210754B1/en unknown
-
2007
- 2007-08-17 HR HRP20070360AA patent/HRP20070360B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SA01210754B1 (en) | 2007-02-17 |
| HRP20070360A2 (en) | 2008-12-31 |
| PE20011051A1 (en) | 2001-10-17 |
| UA81388C2 (en) | 2008-01-10 |
| HRP20070360B1 (en) | 2014-11-21 |
| JO2334B1 (en) | 2006-06-28 |
| AR035633A1 (en) | 2004-06-23 |
| UA89180C2 (en) | 2010-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2245713C2 (en) | Interrupted hormone-substitution therapy with low estrogen dosages | |
| ME00292B (en) | Drospirenone for hormone replacement therapy | |
| ES2399105T3 (en) | Quadriphasic estrogen contraceptive continuously graduated | |
| AR031563A1 (en) | A PHARMACEUTICAL COMPOSITION FOR EMPLOYMENT IN THE TREATMENT OF MENOPAUSIC OR POSMENOPAUSIC DISORDERS OF STROGENS AND MEDROXIPROGESTERONE ACETATE, A PHARMACEUTICAL DOSAGE UNIT AND USE OF A CONJUGATED STRAGEN COMBINATION OF UTROGRAPHIC MANIFORM | |
| RS20090134A (en) | Pharmaceutical combinattion of ethinylestradiol and drospinenone for use as a contraceptive | |
| KR20090080989A (en) | USE OF ESTRADIOL VALERATE OR 17beta-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO | |
| EP1482948B1 (en) | Continuous sulfatase inhibiting progestogen hormone replacement therapy | |
| SK282921B6 (en) | Hormone replacement therapy | |
| CA2487268A1 (en) | Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm | |
| CO5590926A2 (en) | USE OF ANASTROZOL FOR THE TREATMENT OF POSMENOPAUSIC WOMEN WHO HAVE A BREASTFUL CANCER | |
| ES2293215T3 (en) | USE OF A COMBINATION OF AN AROMATASE INHIBITOR, A PROGESTAGEN AND A STROGEN FOR THE TREATMENT OF ENDOMETRIOSIS. | |
| UA81387C2 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| CO5280075A1 (en) | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY | |
| ES2230711T3 (en) | COMBINATIONS OF ENDOMETRIAL CONSERVATION PROGESTINES AND ENDOMETRIAL ATROPHY PROGESTINES WITH STROGENS, IN ORAL ANTI-CONCEPTION. | |
| ES2260792T3 (en) | SEQUENTIAL COMBINATION OF A STROGEN AND A PROGESTERONE ANTAGONIST FOR THERAPY THROUGH HORMONE REPLACEMENT. | |
| ES2316402T3 (en) | MESOPROGESTAGENOS (MODULATORS OF PROGESTERONE RECEPTORS) AS A COMPONENT COMPONENT FOR RESTITUTIVE HORMONOTHERAPY (HRT). | |
| AR043470A2 (en) | A PHARMACEUTICAL COMPOSITION TO BE USED AS AN CONTRACEPTIVE | |
| Moghadam et al. | Advances in menopausal hormonal therapy delivery systems: a comparative review | |
| Panay et al. | Pulsed estrogen therapy: a new concept in hormone replacement therapy | |
| TH134365B (en) | Drospirinone for hormone replacement therapy | |
| JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive | |
| TH54054B (en) | Pharmaceutical mixtures for use as birth control pills | |
| UY26539A1 (en) | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY. | |
| HRP20020666A8 (en) | Drospirenone for hormone replacement therapy | |
| TH134365A (en) | Drospirinone for hormone replacement therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |